Virginia Tech Carilion Research Institute and School of Medicine, Roanoke, VA, USA; Graduate Program in Translational Biology, Medicine, and Health, Virginia Tech, Blacksburg, VA, USA; Center for Heart and Regenerative Medicine, Virginia Tech Carilion Research Institute, Roanoke, VA, USA.
Virginia Tech Carilion Research Institute and School of Medicine, Roanoke, VA, USA; Department of Biological Sciences, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA; Center for Heart and Regenerative Medicine, Virginia Tech Carilion Research Institute, Roanoke, VA, USA.
Life Sci. 2018 Nov 1;212:138-144. doi: 10.1016/j.lfs.2018.09.054. Epub 2018 Oct 2.
Eukaryotic mRNAs were historically thought to rely exclusively on recognition and binding of their 5' cap by initiation factors to effect protein translation. While internal ribosome entry sites (IRESs) are well accepted as necessary for the cap-independent translation of many viral genomes, there is now recognition that eukaryotic mRNAs also undergo non-canonical modes of translation initiation. Recently, high-throughput assays have identified thousands of mammalian transcripts with translation initiation occurring at non-canonical start codons, upstream of and within protein coding regions. In addition to IRES-mediated events, regulatory mechanisms of translation initiation have been described involving alternate 5' cap recognition, mRNA sequence elements, and ribosome selection. These mechanisms ensure translation of specific mRNAs under conditions where cap-dependent translation is shut down and contribute to pathological states including cardiac hypertrophy and cancer. Such global and gene-specific dynamic regulation of translation presents us with an increasing number of novel therapeutic targets. While these newly discovered modes of translation initiation have been largely studied in isolation, it is likely that several act on the same mRNA and exquisite coordination is necessary to maintain 'normal' translation. In this short review, we summarize the current state of knowledge of these alternative mechanisms of eukaryotic protein translation, their contribution to normal and pathological cell biology, and the potential of targeting translation initiation therapeutically in human disease.
真核生物 mRNAs 传统上被认为完全依赖于起始因子对其 5' 帽的识别和结合,从而实现蛋白质翻译。虽然内部核糖体进入位点(IRESs)被广泛认为是许多病毒基因组无帽依赖翻译所必需的,但现在已经认识到真核生物 mRNAs 也经历非典型的翻译起始模式。最近,高通量测定方法已经鉴定出数千种哺乳动物转录物,其翻译起始发生在非典型起始密码子上,位于蛋白质编码区的上游和内部。除了 IRES 介导的事件外,还描述了翻译起始的调节机制,涉及替代 5' 帽识别、mRNA 序列元件和核糖体选择。这些机制确保在依赖帽的翻译被关闭的情况下翻译特定的 mRNAs,并有助于包括心脏肥大和癌症在内的病理状态。这种翻译的全局和基因特异性动态调节为我们提供了越来越多的新的治疗靶点。虽然这些新发现的翻译起始模式在很大程度上是孤立研究的,但很可能有几种模式作用于同一 mRNAs,并且需要精细的协调来维持“正常”的翻译。在这篇简短的综述中,我们总结了这些真核生物蛋白翻译的替代机制的现有知识状态,它们对正常和病理细胞生物学的贡献,以及在人类疾病中靶向翻译起始治疗的潜力。